GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nu-Med Plus Inc (OTCPK:NUMD) » Definitions » Altman Z-Score

Nu-Med Plus (Nu-Med Plus) Altman Z-Score : N/A (As of Jun. 09, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nu-Med Plus Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Nu-Med Plus has a Altman Z-Score of N/A, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Nu-Med Plus's Altman Z-Score or its related term are showing as below:

During the past 13 years, Nu-Med Plus's highest Altman Z-Score was 429.09. The lowest was -950.93. And the median was 21.40.


Nu-Med Plus Altman Z-Score Historical Data

The historical data trend for Nu-Med Plus's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nu-Med Plus Altman Z-Score Chart

Nu-Med Plus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nu-Med Plus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nu-Med Plus's Altman Z-Score

For the Medical Devices subindustry, Nu-Med Plus's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nu-Med Plus's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nu-Med Plus's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Nu-Med Plus's Altman Z-Score falls into.



Nu-Med Plus Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Nu-Med Plus's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-18.7778+1.4*-1094.1111+3.3*-12.7778+0.6*23.5169+1.0*0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $0.01 Mil.
Total Current Assets was $0.01 Mil.
Total Current Liabilities was $0.18 Mil.
Retained Earnings was $-9.85 Mil.
Pre-Tax Income was -0.022 + -0.057 + -0.016 + -0.024 = $-0.12 Mil.
Interest Expense was -0.001 + -0.001 + -0.001 + -0.001 = $-0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Market Cap (Today) was $4.19 Mil.
Total Liabilities was $0.18 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.009 - 0.178)/0.009
=-18.7778

X2=Retained Earnings/Total Assets
=-9.847/0.009
=-1094.1111

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-0.119 - -0.004)/0.009
=-12.7778

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=4.186/0.178
=23.5169

X5=Revenue/Total Assets
=0/0.009
=0

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Nu-Med Plus has a Altman Z-Score of N/A indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Nu-Med Plus  (OTCPK:NUMD) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Nu-Med Plus Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Nu-Med Plus's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Nu-Med Plus (Nu-Med Plus) Business Description

Traded in Other Exchanges
N/A
Address
640 Belle Terre Road, Building 2 E Port, Jefferson, NY, USA, 11777
Nu-Med Plus Inc is an medical device company principally engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems and medical community throughout the world.
Executives
William C Hayde director, officer: CEO 76 CLIFF ROAD, BELLE TERRE NY 11777
Wendy P. Smith 10 percent owner P. O. BOX 1374, SALT LAKE CITY UT 84110
Brett J. Earl director, officer: VP of Medical Marketing P.O. BOX 729, MORGAN UT 84050
Mark Edward Christensen officer: CFO, Sec, Treas, Prin Acct Off 455 E. 500 S., SUITE 207, SALT LAKE CITY UT 84111
Thomas A Tait 10 percent owner 514 AMERICAS WAY #5556, BOX ELDER SD 57719
Craig Morrison director, 10 percent owner, officer: Vice President of Technology 975 NORTH TERRACE DRIVE, PROVO UT 84604
William G Moon director, 10 percent owner, officer: Vice President of Operations 1266 SOUTH 1380 WEST, OREM UT 84058
Jeffrey Lynn Robins director, 10 percent owner, officer: CEO 455 EAST 500 SOUTH, SUITE #205, SALT LAKE CITY UT 84111